<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35437759</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Comparative analysis of the biological characteristics of three CV-A10 clones adaptively cultured on Vero cells.</ArticleTitle><Pagination><StartPage>3820</StartPage><EndPage>3828</EndPage><MedlinePgn>3820-3828</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27796</ELocationID><Abstract><AbstractText>Coxsackievirus A10 (CV-A10) is a major pathogen that causes hand, foot, and mouth disease. There are no effective therapeutic drugs for CV-A10 infection; therefore, CV-A10 vaccines should be developed. Previously, we isolated a CV-A10 strain (N25) that can be cultured on Vero cells. In this study, the N25 strain was plaque-purified three times from Vero cells, and three clones were selected for adaptive culture. The three clones of the 5th, 12th, and 19th generations were compared and analyzed in terms of viral titers, plaque morphology, pathogenicity in suckling mice, and nucleotide and amino acid sequences of the complete genome. The infectivity titers of the three clones (P2-P22) were maintained at 6.5-7.0 lgCCID<sub>50</sub> /ml. The three clones began to proliferate at 6 h and peaked at 36 h; the corresponding CCID<sub>50</sub> was in the range of 10<sup>6.5</sup> -10<sup>6.875</sup> /ml, which gradually decreased. The suckling mice in the challenged group exhibited clinical symptoms such as paralysis of the limbs, which gradually worsened until death. The inactivated vaccines prepared using the three clones efficiently induced antigen-specific serum antibodies in mice. There were eight nucleotide mutations in the three clones, which resulted in two and four amino acid substitutions in the VP3 and VP1 coding regions, respectively. The nucleotide and amino acid sequence homology between the three clones and N25 were 99.92%-100% and 99.78%-100%, respectively, indicating high genetic stability. Our findings provide a theoretical basis for screening CV-A10 vaccine candidate clones.</AbstractText><CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4762-7252</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tianhong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xingchen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuhao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhongping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academic Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory for Vaccine Research and Development of Major Infectious Diseases in Yunnan Province, Kunming, Yunnan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044482">Benzeneacetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009711">Nucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010881">Piperidones</NameOfSubstance></Chemical><Chemical><RegistryNumber>16VY3TM7ZO</RegistryNumber><NameOfSubstance UI="C052091">antineoplaston A10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044482" MajorTopicYN="N">Benzeneacetamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009711" MajorTopicYN="N">Nucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010881" MajorTopicYN="N">Piperidones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus</Keyword><Keyword MajorTopicYN="N">vaccines/vaccine clones</Keyword><Keyword MajorTopicYN="N">virulence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35437759</ArticleId><ArticleId IdType="doi">10.1002/jmv.27796</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Bian L, Gao F, Mao Q, et al. Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev Anti Infect Ther. 2019;17(4):233-242.</Citation></Reference><Reference><Citation>Bracho MA, González-Candelas F, Valero A, Córdoba J, Salazar A. Enterovirus co-infections and onychomadesis after hand, foot, and mouth disease, Spain, 2008. Emerg Infect Dis. 2011;17(12):2223-2231.</Citation></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14(12):e1076-e1081.</Citation></Reference><Reference><Citation>Blomqvist S, Klemola P, Kaijalainen S, et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48(1):49-54.</Citation></Reference><Reference><Citation>Gonzalez G, Carr MJ, Kobayashi M, Hanaoka N, Fujimoto T. Enterovirus-associated hand-foot and mouth disease and neurological complications in Japan and the rest of the world. Int J Mol Sci. 2019;20(20):5201.</Citation></Reference><Reference><Citation>Mirand A, Henquell C, Archimbaud C, et al. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect. 2012;18(5):E110-E118.</Citation></Reference><Reference><Citation>Li J, Wang X, Cai J, et al. Non-polio enterovirus infections in children with central nervous system disorders in Shanghai, 2016-2018: Serotypes and clinical characteristics. J Clin Virol. 2020;129:104516.</Citation></Reference><Reference><Citation>Xie J, Yang XH, Hu SQ, et al. Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China. BMC Infect Dis. 2020;20(1):271.</Citation></Reference><Reference><Citation>He YQ, Chen L, Xu WB, et al. Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6- and coxsackievirus a10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. J Clin Microbiol. 2013;51(11):3560-3566.</Citation></Reference><Reference><Citation>Tian H, Zhang Y, Sun Q, et al. Prevalence of multiple enteroviruses associated with hand, foot, and mouth disease in Shijiazhuang City, Hebei province, China: outbreaks of coxsackieviruses a10 and b3. PLoS One. 2014;9(1):e84233.</Citation></Reference><Reference><Citation>Chen M, He S, Yan Q, et al. Severe hand, foot and mouth disease associated with Coxsackievirus A10 infections in Xiamen, China in 2015. J Clin Virol. 2017;93:20-24.</Citation></Reference><Reference><Citation>Frydenberg A, Starr M. Hand, foot and mouth disease. Aust Fam Physician. 2003;32(8):594-595.</Citation></Reference><Reference><Citation>Zhao TS, Du J, Li HJ, et al. Molecular epidemiology and clinical characteristics of herpangina children in Beijing, China: a surveillance study. PeerJ. 2020;8:e9991.</Citation></Reference><Reference><Citation>Kumar A, Shukla D, Kumar R, et al. Molecular identification of enteroviruses associated with aseptic meningitis in children from India. Arch Virol. 2013;158(1):211-215.</Citation></Reference><Reference><Citation>Okada H, Wada M, Sato H, et al. Neuromyelitis optica preceded by hyperCKemia and a possible association with coxsackie virus group A10 infection. Intern Med. 2013;52(23):2665-2668.</Citation></Reference><Reference><Citation>Fuschino ME, Lamson DM, Rush K, et al. Detection of coxsackievirus A10 in multiple tissues of a fatal infant sepsis case. J Clin Virol. 2012;53(3):259-261.</Citation></Reference><Reference><Citation>Liu CC, Guo MS, Wu SR, et al. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58-66.</Citation></Reference><Reference><Citation>Gao W, Yue L, Yang T, et al. A comparative study on biological characteristics of ten coxsackievirus A10 virus strains. Virology. 2021;555:1-9.</Citation></Reference><Reference><Citation>Guo WP, Lin XD, Chen YP, et al. Fourteen types of co-circulating recombinant enterovirus were associated with hand, foot, and mouth disease in children from Wenzhou, China. J Clin Virol. 2015;70:29-38.</Citation></Reference><Reference><Citation>Zhou Y, Zhang C, Liu Q, Gong S, Geng L, Huang Z. A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124-130.</Citation></Reference><Reference><Citation>Zhang Z, Dong Z, Li J, et al.Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol. 2017;91(13):e00333-17.</Citation></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94.</Citation></Reference><Reference><Citation>Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818-828.</Citation></Reference><Reference><Citation>Li S, Zhao H, Yang L, et al. A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Res. 2017;144:247-255.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>